Access cutting-edge non-muscle invasive bladder carcinoma treatment through this clinical trial at a research site in Columbus. Study-provided care at no cost to qualified participants.
Quick Self-Assessment
See if you qualify for this Columbus location
Preparing your pre-screening questions…
Access non-muscle invasive bladder carcinoma specialists at no cost
This study follows strict safety protocols and ethical guidelines
All study-related non-muscle invasive bladder carcinoma treatment provided free
Check if you qualify for this non-muscle invasive bladder carcinoma clinical trial in Columbus, OH
No-Cost Study Care
Local to Columbus
Convenient for OH residents
Cutting-Edge Treatment
Access to innovative therapies
Expert Medical Care
Close monitoring by specialists
Possible Compensation*
For time and travel
*Compensation varies by study. Confirm details with coordinator.
This phase IV trial studies whether there is a relationship between how a patient is positioned while receiving bacillus Calmette Guerin (BCG) within the bladder (intravesical) and how long BCG stays in the bladder (dwell time) to improve the treatment of non-muscle invasive bladder cancer. For the past 40 years, intravesical BCG has been used for the treatment of non-muscle invasive bladder cancer. An important factor for BCG treatment is the dwell time, which is the period of time a patient can hold the BCG medication in the bladder after it has been given. Normally, patients are instructed during intravesical BCG treatment to avoid emptying the bladder for 2 hours after the BCG is given. However, this may be difficult for some patients who may have limited bladder capacity, restricted movement, or severe urinary symptoms. There have been studies outlining the relationship with increased dwell time and how well the treatment works, but studies on the potential impact of patient positioning or activity on the patient's ability to retain the drug are limited. Researchers hope by studying whether there is a relationship between patient positioning during intravesical BCG treatment and dwell time, they may be able to improve how BCG treatment for non-muscle invasive bladder cancer is given, especially for patients with limited bladder capacity, restricted movement, or severe urinary symptoms.
Sponsor: Ohio State University Comprehensive Cancer Center
Yes, this clinical trial (NCT07474519) has an active research site in Columbus, OH that is currently enrolling participants.
Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.
Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.
Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.
If you're searching for non-muscle invasive bladder carcinoma treatment options in Columbus, OH, this clinical trial (NCT07474519) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Columbus research site is actively enrolling participants for this clinical trial. You'll receive care from experienced non-muscle invasive bladder carcinoma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.
Looking for more options? Browse all non-muscle invasive bladder carcinoma clinical trials near you to find additional studies recruiting in your area.
See all bladder cancer clinical trials recruiting in Columbus — not just this study.
Browse Bladder Cancer Trials in Columbus →